Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 6/20 | 0.67 |
| ▸ | SYK | P43405 | 6/20 | 0.62 |
| ▸ | EGFR | P00533 | 6/20 | 0.58 |
| ▸ | ITK | Q08881 | 3/20 | 0.58 |
| ▸ | BTK | Q06187 | 2/20 | 0.58 |
| ▸ | JAK2 | O60674 | 1/20 | 0.58 |
| ▸ | LYN | P07948 | 1/20 | 0.58 |
| ▸ | TEC | P42680 | 1/20 | 0.58 |
| ▸ | TXK | P42681 | 1/20 | 0.58 |
| ▸ | BMX | P51813 | 1/20 | 0.58 |
| ▸ | JAK3 | P52333 | 1/20 | 0.58 |
| ▸ | CD69 | Q07108 | 1/20 | 0.58 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.53 |
| ▸ | CDK4 | P11802 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25068898 | 0.87 | SYK (0.59) | AURKASYKEGFRITKBTK | |
| SCHEMBL23408964 | 0.85 | SYK (0.68) | AURKASYKEGFRITKBTK | |
| SCHEMBL30843982 | 0.85 | EGFR (0.61) | AURKASYKEGFRITKBTK | |
| SCHEMBL28715181 | 0.85 | EGFR (0.61) | AURKASYKEGFRITKBTK | |
| SCHEMBL28716958 | 0.84 | EGFR (0.61) | AURKASYKEGFRITKBTK | |
| SCHEMBL29412027 | 0.84 | BTK (0.65) | AURKASYKEGFRITKBTK | |
| SCHEMBL28715173 | 0.84 | BTK (0.65) | AURKASYKEGFRITKBTK | |
| SCHEMBL23409017 | 0.83 | SYK (0.68) | AURKASYKEGFRITKBTK | |
| SCHEMBL22909543 | 0.83 | SYK (0.69) | AURKASYKEGFRITKBTK | |
| SCHEMBL25068921 | 0.83 | SYK (0.64) | AURKASYKEGFRITKBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018153-A1 | BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | 2692372 ONTARIO, INC. (CA) | 2024-01-18 | — | — | US | disclosed |
| WO-2021099842-A1 | PENTAFLUOROBENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | 2692372 ONTARIO INC. (CA) | 2021-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018153-A1 | BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | ABCG2, ABCB1, ARSA | AURKA 2089/4885SYK 610/4885EGFR 2252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.